Amgen (AMGN) Reports Positive Phase 3 TEZSPIRE Results In Eosinophilic Esophagitis

What happened: Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive full Phase 3 results for TEZSPIRE in eosinophilic esophagitis (EoE), with improvements in symptoms and endoscopic endpoints sustained through one year. Key numbers: Market value about $241.8b; fair value cited at $391; improvements sustained through one year. Why it matters: The data is described as an incremental step supporting Amgen's immunology story, fitting the view that targeted biologics can broaden the portfolio and help offset loss of exclusivity and U.S. pricing pressure.

Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive full Phase 3 results for TEZSPIRE in eosinophilic esophagitis (EoE), with improvements in symptoms and endoscopic endpoints sustained through one year.

The data is described as an incremental step supporting Amgen's immunology story, fitting the view that targeted biologics can broaden the portfolio and help offset loss of exclusivity and U.S. pricing pressure.